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OBJECTIVE—Genome-wide association studies that compare
the statistical association between thousands of DNA variations
and a human trait have detected 958 loci across 127 different
diseases and traits. However, these statistical associations only
provide evidence for genomic regions likely to harbor a causal
gene(s) and do not directly identify such genes. We combined
gene variation and expression data in a human cohort to identify
causal genes.
RESEARCH DESIGN AND METHODS—Global gene tran-
scription activity was obtained for each individual in a large
human cohort (n  1,240). These quantitative transcript data
were tested for correlation with genotype data generated from
the same individuals to identify gene expression patterns inﬂu-
enced by the variants.
RESULTS—Variant rs8050136 lies within intron 1 of the FTO
gene on chromosome 16 and marks a locus strongly associated
with type 2 diabetes and obesity and widely replicated across
many populations. We report that genetic variation at this locus
does not inﬂuence FTO gene expression levels (P  0.38), but is
strongly correlated with expression of RBL2 (P  2.7  10
5),
270,000 base pairs distant to FTO.
CONCLUSIONS—These data suggest that variants at FTO in-
ﬂuence RBL2 gene expression at large genetic distances. This
observation underscores the complexity of human transcrip-
tional regulation and highlights the utility of large human cohorts
in which both genetic variation and global gene expression data
are available to identify disease genes. Expedient identiﬁcation
of genes mediating the effects of genome-wide association study–
identiﬁed loci will enable mechanism-of-action studies and
accelerate understanding of human disease processes under
genetic inﬂuence. Diabetes 59:726–732, 2010
T
he identiﬁcation of genes contributing to disease
development in humans will provide medical
beneﬁts in two ways. First, the deﬁning of caus-
ative risk predisposing genetic variation will
allow improvements to be made to current clinical risk
models for disease onset and progression. Second, knowl-
edge of the gene’s identity that mediates the biological
consequences of this variation will improve understanding
of the molecular pathways that participate in disease
pathogenic processes. Genome-wide association studies
have yielded 958 loci associated with 127 human diseases
and traits over the past several years (1). Yet these
associations, like many successful genetic linkage analysis
studies that predate them (2), only identify a genetic
region or loci and do not directly locate the causative
variant(s). Without comprehensive sequence information
to achieve better resolution, the associated variant may
merely be in linkage disequilibrium with another untyped
functional variant. Depending upon the population and
sample design, the span of potential linkage disequilibrium
may easily be as large as 500 kb (3) and potentially much
larger (4). Alternatively, the observed associated variant
may be directly functional, working to modulate transcrip-
tional elements operating at large genetic distances. With-
out disease gene identiﬁcations, the beneﬁts to medicine
cannot be fully realized.
A major limitation to identiﬁcation of the genes through
which these loci cause disease has been the dearth of
large-scale cohorts in which both gene expression and
genotype data have been measured in the same individuals
(5). In this study, we analyze the San Antonio Family Heart
Study (SAFHS), where large-scale gene expression and
variation measurements have been undertaken in the same
individuals (6) and demonstrate its utility in identiﬁcation
of genes mediating the consequences of biological varia-
tion. We apply this approach to the FTO locus (Entrez
GeneID: 79068) that was the most strongly associated
region identiﬁed by genome-wide association study that
predisposes to type 2 diabetes through an effect on body
mass (7–10) and has been widely replicated (11). These
data indicate that human transcriptional regulation is
more complex than has been previously anticipated.
RESEARCH DESIGN AND METHODS
Ethics statement. All study participants provided informed consent. The
study and all protocols presented here were approved by the Institutional
Review Board at the University of Texas Health Science Center at San
Antonio.
Study population. This study was based on participants in the San Antonio
Family Heart Study (12), which focuses on genetic aspects of cardiovascular
health and disease in Mexican Americans.
Expression proﬁling. Total RNA was isolated from lymphocyte samples
from 1,240 individuals and gene expression measured by hybridization of
labeled cRNA to Illumina Sentrix Human Whole Genome (WG-6) Series I
BeadChips and scanning on the Illumina BeadArray 500GX Reader as described
previously (6) and in the supplementary methods section, available in an online
appendix at http://diabetes.diabetesjournals.org/content/full/db09-1277/DC1.
Identiﬁcation of expressed transcripts. To identify transcripts that exhib-
ited sufﬁcient quantitative expression in lymphocytes, the distribution of
expression values for a given transcript was compared with the distribution of
the expression values of the controls that are embedded in each chip. For each
transcript, we performed a 
2 “tail” test of whether there was a signiﬁcant
From the
1Department of Genomics and Systems Biology, Baker IDI Heart and
Diabetes Institute, Melbourne, Victoria, Australia; and the
2Department of
Genetics, Southwest Foundation for Biomedical Research, San Antonio,
Texas.
Corresponding author: Jeremy B.M. Jowett, jeremy.jowett@bakeridi.edu.au.
Received 27 August 2009 and accepted 1 December 2009. Published ahead of
print at http://diabetes.diabetesjournals.org on 15 December 2009. DOI:
10.2337/db09-1277.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
726 DIABETES, VOL. 59, MARCH 2010 diabetes.diabetesjournals.orgexcess of samples with values above the 95th percentile of the control null
distribution. This test was used because it allows detection of even those
transcripts that are clearly present above baseline levels in only a subset of
individuals, but not detectable at these levels in most individuals. Using a false
discovery rate of 0.05, we identiﬁed 20,413 transcripts that exhibited signiﬁ-
cant expression by this criterion (6).
Standardization of expression values. To minimize the inﬂuence of overall
signal levels, which may reﬂect RNA quantity and quality rather than a true
biological difference among individuals, abundance values of all 20,413
retained transcripts were ﬁrst standardized by z scoring within individuals
(using decile percentage bins of transcripts, grouped by average log-trans-
formed raw signals across individuals), followed by linear regression against
individual-speciﬁc average log-transformed raw signal and its squared value.
Lastly, for each transcript, we directly normalized these residual expression
scores using an inverse Gaussian transformation across individuals, to ensure
that the assumptions underlying variance component–based analyses were
not violated. This conservative procedure results in normalized expression
phenotypes that are comparable among individuals and across transcripts (6).
Microsatellite marker genotyping. The Human MapPairs Genome-Wide
Screening Set Versions 6 and 8 from Research Genetics (Huntsville, AL) were
used. Genotyping occurred according to the manufacturer’s instructions by
PCR on lymphocyte-derived DNA samples from study participants. The PCR
products were subsequently pooled into multiplex panels for genotype calling
on an automated DNA sequencer (model 377 with Genescan 672 and Geno-
typer software programs; Applied Biosystems, Foster City, CA). Overall, 1,345
individuals were genotyped at 432 highly polymorphic microsatellite markers,
distributed with average intermarker spacing of 10 cM across all 22
autosomes. The median distance between the detected autosomal transcripts
and the nearest marker is 2.7 cM, and 80 and 90% of transcripts are within
4.3 and 5.5 cM from the nearest marker, respectively. These genotypes were
subjected to extensive data cleaning that has been previously described (6).
Single nucleotide polymorphism genotyping. The Illumina HumanHap550
Genotyping BeadChip was used to genotype single nucleotide polymorphisms
(SNPs) in 858 individuals in whom gene expression data were available using
the Inﬁnium II Assay (Illumina, San Diego, CA). The Inﬁnium II Assay
combines a single-tube, whole-genome ampliﬁcation method with direct,
array-based capture and enzymatic scoring of the SNP loci. Locus discrimi-
nation is provided by a combination of sequence-speciﬁc hybridization
capture and array-based, single-base primer extensions. A single primer is
used to interrogate a SNP locus. The 3 end of the primer is juxtaposed to the
SNP site, and extension of the primer incorporates a biotin-labeled nucleotide
(C or G) or a dinitrophenyl-labeled nucleotide (A or T). Signal ampliﬁcation of
the incorporated label further improves the overall signal-to-noise ratio of the
assay. The Inﬁnium II genotyping was performed using Illumina’s standard
protocols on a Tecan Freedom Evo Robot. After staining, each BeadChip was
imaged on the Illumina BeadArray 500GX Reader using Illumina BeadScan
image data acquisition software (Version 3.2.6). Genotype data were then
assessed using the Genotyping Module of Illumina’s BeadStudio software
(Version 2.0).
Genotype data cleaning. Multivariate methods generally require that indi-
viduals with missing data be excluded from the analysis, which can result in
a signiﬁcant decrease in sample size. To minimize this issue, we used
likelihood-based imputation with the MERLIN computer package as has been
previously described (6) to rapidly impute SNP data in pedigrees. For each
pedigree, imputation is performed and the posterior genotypic probabilities
for each missing genotype are stored. These posterior probabilities are used to
construct an appropriately weighted covariate for each SNP that is then used
in association analyses.
To eliminate the potential for hidden population stratiﬁcation that the
standard ﬁxed-effect association approach is susceptible to, we also used the
quantitative transmission disequilibrium test approach to association testing
implemented in SOLAR (13). Although this approach exhibits substantially
decreased power than measured genotype analysis (14), it maintains the
appropriate signiﬁcance levels under the null hypothesis, even in the presence
of population stratiﬁcation. However, because of its poor power, we used it
only as a check to identify consistence of qualitative inferences drawn from
measured genotype analysis.
Statistical genetic analysis: linkage and association. All statistical anal-
yses on related individuals were performed using variance component–based
methodology and software package SOLAR Version 4.0 (15). As preparation
for linkage analysis, the probabilities of multipoint identity-by-descent allele
sharing among pairs of related individuals were computed by the Monte Carlo
Markov chain multipoint approach implemented in software package Loki
(16), using the genotypes at all linked markers jointly in the computations.
Maximum likelihood marker allele frequencies were used as previously
described (6). Covariates were included in the variance components frame-
work as linear predictors of phenotype. Measured genotype analysis (17),
embedded in a variance component–based linkage model, was used for
association testing, assuming an additive model of allelic effect (i.e., the SNP
genotypes AA, AB, and BB were coded as 1, 0, and 1, respectively, and used
as a linear predictor of phenotype) (13).
Correction for multiple testing. To correct for the effect of multiple testing
for a given phenotype, we estimated the effective number of SNPs using the
method of Li and Ji (18), which uses a modiﬁcation of an earlier approach by
Nyholt (19). After obtaining the effective number of SNPs, we used a modiﬁed
Bonferroni procedure to identify a target  level that would maintain an
overall signiﬁcance level of 0.05.
Heritability analysis. Heritability analysis was performed under the classi-
cal approach decomposing the phenotypic variance into independent genetic
and environmental components, assuming an additive model of gene action
(“narrow sense” heritability) and expected kinship coefﬁcients based on the
observed intrafamilial relationships.
RESULTS
Expression proﬁles were obtained from the lymphocytes
of 1,240 individuals in the SAFHS (6). The potential
consequences of variants genotyped in this cohort were
assessed by performing correlation analysis of the genetic
variation using a measured genotype approach with the
high-dimensional quantitative expression data.
The obesity-associated locus within the FTO gene is a
47-kb region of high linkage disequilibrium (LD) that spans
part of intron 1, all of exon 2, and part of intron 2 of the
FTO gene. Two SNPs in this region, rs8050136 and
rs9939609, are in high LD (r
2 	 0.95) with each other and
have been strongly associated with type 2 diabetes (P 
5.2  10
8) (20) and obesity (P  1.1  10
47) (11). We
examined the association of rs8050136 with levels of
transcripts up to 5 Mb in either direction of the SNP. No
association with FTO gene expression was observed (P 
0.54; n  854); however, a strong association was ob-
served with the retinoblastoma-like 2 (RBL2; Entrez Ge-
neID: 5934) transcript (P  1.5  10
5; n  854) that is
located 270 kb proximal to FTO (Fig. 1).
To avoid missing the potential effects of untyped genetic
variation and capture of the combined effects of all genetic
variation in the region on RBL2 and FTO expression, we
performed multipoint genetic linkage analysis on chromo-
some 16 using RBL2 and FTO transcript levels as expres-
sion quantitative traits. Linkage analysis was conducted on
highly polymorphic simple tandem repeat markers that
have been previously described in this cohort (12). We
observed a nominally signiﬁcant linkage signal for RBL2
expression (logarithm of odds [LOD] score  0.997, P 
0.016; n  1,240) but not FTO expression directly at the
RBL2-FTO locus (Fig. 2), indicating that only RBL2 ex-
pression is likely to be affected by genetic variation in this
region.
To identify the genetic variation in this region responsi-
ble for the observed linkage signal and to test whether
rs8050136 was a contributor, we genotyped 136 SNPs
spanning 706 kb in 858 of the same individuals in whom
expression levels were measured. We observed strong
association of several groups of variants with RBL2 ex-
pression using the measured genotype test, one of which
included rs8050136 (P  1.5  10
5; Fig. 3 and supplemen-
tary Table 1). Two other regions showed strong associa-
tion, one located directly at the location of the RBL2
structural gene itself (rs8043918; P  1.8  10
17), poten-
tially affecting local promoter elements, and the second
region 87.4 kb distal to rs8050136 at 52.5 Mb and within the
FTO gene, but spanning introns 4 and 5 and exon 5 of FTO
(rs7197983; P  3.8  10
8). The associations remained
signiﬁcant after adjustment for multiple testing after al-
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4). To determine
whether these associations were independent of back-
ground linkage, we undertook the quantitative transmis-
sion disequilibrium test, which is resistant to inﬂation of
type I error rate in the presence of linkage (14). The
following P values were observed for association with
RBL2: rs8050136, P  0.006; rs8043918, P  6.6  10
5;
and rs7197983, P  0.027, suggesting that these associ-
ations are independent of background linkage (supple-
mentary Table 1). The variants were also tested for
association with FTO gene expression, but none re-
mained signiﬁcant after adjustment for multiple testing
(supplementary Table 1).
The minor allele frequency (MAF) of rs8050136 (A
allele) was 0.23 in the SAFHS, consistent with prior data in
the Mexican American population (MAF  0.20) (21) and
lower than that observed in the CEPH (Utah residents with
ancestry from northern and western Europe) cohort
(MAF  0.46) and Yoruba in Ibadan, Nigeria (MAF  0.46),
but higher than the Han Chinese in Beijing, China (MAF 
0.14), and Japanese in Tokyo cohorts (MAF  0.18). We
observed a similar 40-kb region of high LD (r
2 	 0.5)
around rs8050136 and rs9939609 that rapidly fell outside
this interval as previously reported (10).
We performed conditional linkage analysis to determine
whether rs8050136 contributed to the observed linkage
signal for RBL2 gene expression. Incorporation of
rs8050136 into the linkage model as a covariate reduced
the LOD score from 0.997 to 0.201 (Fig. 4B). Further
addition of the two SNPs most strongly associated with
RBL2 expression levels (rs8043918 and rs9921587; n 
852) reduced the LOD score to zero (Fig. 4C), indicating
that either these variants or those correlated with them
account for the majority of the observed linkage signal,
although the contribution of additional variants of small
effect size cannot be ruled out.
The initial observation of association of rs8050136 and
rs9939609 was with type 2 diabetes; however, after adjust-
ment for BMI, the association was abrogated (10). We
tested for association of rs8050136 with type 2 diabetes in
the SAFHS and observed a nominal association (P 
0.050). Furthermore, and consistent with its initial discov-
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FIG. 1. Association of the rs8050136 SNP with expression levels of genes within 5 Mb of the SNP coordinate in 854 individuals. Strong association
of the SNP with RBL2 is observed, whereas no association with FTO is seen. The intron/exon structure of the genes in this region is illustrated
by the lines and blocks beneath the x-axis (thin line, intron; block, exon). The negative log of the P value is plotted against the coordinates in
megabase pairs (Mb). The horizontal line on the y-axis at 2.2 indicates the P value for experiment-wide signiﬁcance following adjustment for
multiple testing (P  0.0063).
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FIG. 2. Multipoint genetic linkage analysis on chromosome 16 for RBL2 and FTO gene expression. Genome-wide linkage analysis for RBL2
expression (A) and FTO expression (B) is shown for 1,240 individuals and reveals a linkage signal on chromosome 16 for RBL2 but not for FTO.
The LOD score is indicated on the y-axis, and the genetic coordinates are shown on the x-axis in centimorgans (cM). The black arrows indicate
the structural position of the RBL2 and FTO genes.
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0.20). The strength of this association is lower than that
previously reported, likely due to the smaller sample size
(n  854) in the SAFHS cohort; however, the observed
trend is consistent with prior published data. Although we
observed no association between FTO and RBL2 expres-
sion levels with diabetes traits, the SNP most strongly
associated with RBL2 expression (rs8043918) exhibited
nominal association with diabetes status (P  0.047) and
homeostasis model assessment–insulin resistance (HOMA-
IR) (P  0.028) after adjustment for BMI.
DISCUSSION
The majority of the replicated genome-wide association
studies have identiﬁed variants that lie in intronic or
intergenic regions; however, follow-up on identiﬁcation of
genes mediating the consequence of biological variation
has been problematic because candidate genes may lie
hundreds of kilobases from the variant (1). Mapping
expression quantitative trait loci have the potential to
identify which genes mediate the effects of genetic varia-
tion. We used a large family-based cohort where both
genotype and gene expression data are available from the
same individuals to address the question of which genes
juxtaposed to disease-associated loci confer the biological
consequences of the variation. We examined the most
strongly type 2 diabetes– and obesity-associated loci de-
noted by rs8050136 located in intron 1 of the FTO gene. We
observed no effect of this variant on FTO gene expression
levels, but observed a strong association with RBL2 gene
expression located 270-kb proximal to FTO. Genetic
linkage analysis in the same cohort revealed a modest
linkage signal for RBL2 expression and none for FTO.
Variants typed in this region, including rs8050136, were
signiﬁcantly associated with RBL2 expression and found
to account for the majority of the linkage signal, whereas
no variants were associated with FTO expression after
adjustment for multiple testing. These data implicate
RBL2 as the major contributor to the biological conse-
quences of rs8050136 or genetic variation in LD with it.
The SNPs rs8050136 and rs9939609 that are in high LD
(r
2 	 0.95) have been genotyped in an extensive number of
replication studies that predominantly conﬁrm the original
ﬁndings. Because these replication studies evaluate only
disease association with genotype data, our results are not
in conﬂict with this body of literature.
The lack of correlation of SNPs rs8050136 and rs9939609
with FTO mRNA expression has been previously reported
in human muscle and adipose tissues in a number of
studies. Our data are consistent with these reports. De-
spite the lack of correlation with these SNPs, some human
studies have been able to identify relationships between
FTO mRNA and measures of obesity. In a large cohort of
female Scandinavians (n  306), FTO mRNA was slightly
higher in subcutaneous adipose tissue of obese (BMI 	30
kg/m
2) than in nonobese (BMI 25 kg/m
2) individuals
(22). A second large study of Danish twins (n  496)
similarly observed increased FTO mRNA with increased
BMI (23), as did a smaller Spanish cohort (24). In contrast,
however, a study reported decreased mRNA with in-
creased BMI in a Scandinavian cohort (25). Mouse models
of obesity show decreased FTO mRNA expression with
increased obesity (26), but conﬂict with the study by
Church et al. (27) on an N-ethyl-N-nitrosurea (ENU)–
induced COOH-terminal mutant of FTO (mFTO
I367F)i n
mice that exhibited reduced levels of FTO protein and
decreased body and fat mass. Collectively, it appears that
FTO may play a role in obesity, although the mechanism
remains controversial. In humans, because the SNPs
rs8050136 and rs9939609 consistently fail to correlate with
FTO mRNA expression across multiple tissues, it is plau-
sible that other genes such as the neighboring RBL2 may
participate in mediating these effects and that downstream
processes may have the potential to affect FTO gene
expression indirectly.
We observed nominal association between rs8043918
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FIG. 3. Association of 136 SNPs with RBL2 gene expression levels across the RBL2-FTO gene region in 858 individuals. Three regions of
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adjustment for multiple testing (P  4.9  10
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after adjustment for BMI, suggestive of a potential role
that RBL2 may play in obesity and diabetes. However, the
observed strength of the association prior to adjustment
for multiple testing indicates that the relationship should
be considered preliminary at this stage. Consistent with
this result, we note that in the original genome-wide
association study, genetic variants juxtaposed to RBL2
were nominally associated with type 2 diabetes (P  1 
10
4; 20). Differences in strength of these associations
might be explained by different tiers of transcriptional
control that operate independently and in different circum-
stances according to availability of transcription factors
and temporal development. For example, the locus iden-
tiﬁed within intron 1 of FTO, although 270 kb distant, may
play a speciﬁc role in control of RBL2 gene expression in
a particular tissue type and/or in a speciﬁc stage of
development that inﬂuences obesity. Conversely, genetic
variation directly at the RBL2 locus potentially mediates
their effects through interaction with an alternate set of
transcription factors responding independently to internal
programs and external stimuli and affect cellular proper-
ties that have little impact on development of obesity.
A limitation of this study is its reliance on expression
from a single human tissue and currently a lack of knowl-
edge regarding coordinate gene expression control among
multiple tissues. It is unclear whether gene expression
patterns observed in lymphocytes can be extrapolated to
other tissues such as adipose and muscle; however, in
prior work, valid inferences have been made by such
extrapolations, particularly in the area of central nervous
system disorders (28). Recent studies suggest, however,
that variants affecting gene expression in a consistent
manner among ﬁbroblasts, B-cells, and T-cells are limited
to 17% of genes for two or more tissue types (29).
Additionally, work by Heintzman et al. (30) suggest that
consistency among cell types is dependent upon the type
of expression control region, with promoters and insula-
tors showing highest between–cell type consistency and
enhancer regions showing greatest divergence. Extrapo-
lating these ﬁndings to the FTO-RBL2 locus is difﬁcult
because the control elements for the locus have not been
fully delineated. Our data and that of others show that the
lack of correlation between FTO SNPs and FTO gene
expression was consistently observed across human mus-
cle, adipose, and lymphocyte tissue types (22–26,31),
suggesting this control region may be among those con-
served between cell types. Further investigation into ge-
nome-wide transcriptional analysis across tissues is
warranted in this area, particularly in metabolic disease
given the potential beneﬁts to understanding of disease
processes and development of biomarkers. The SNP
rs8050136 creates a cut-like 1 (CUX1) transcription factor
binding site (26) that may participate in mediating its
biological effects; however, we note that CUX1 is broadly
expressed across human tissue types including adipose,
liver, muscle, and lymphoid (32).
Replication of expression datasets is an important con-
sideration but difﬁcult to achieve. Although large cohorts
exist for replication of genetic variation analyses such as
genome-wide association studies, there are far fewer
large-scale cohorts that contain genome-wide expression
data, making replication of expression-related ﬁndings
problematic. This is further complicated by differences in
tissue types that are relevant to a speciﬁc disease under
investigation. As noted above, some genes share coordi-
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FIG. 4. Conditional genetic linkage analysis of RBL2 gene expres-
sion levels on chromosome 16q12. A: Original linkage for RBL2
expression. B: Addition of rs8050136 as covariate in linkage model.
C: Addition of rs8050136, rs8043918, and rs9921587 as covariates in
linkage model in 852 individuals. LOD score is indicated for the peak
linkage signal under each of the three models. Black arrow denotes
the position of the RBL2 and FTO genes. The y-axis is the LOD
score; the y-axis is the genomic location in centimorgans (cM).
Position of the simple tandem repeat markers is shown across the
top border of each panel.
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do not. Availability of transcription factors in different cell
types as well as methylation patterns contribute to this
diversity. To address this, we and colleagues are seeking
to establish large-scale gene expression replication co-
horts with a range of tissues for analysis, which in the
future may allow expression replication studies to be
undertaken.
RBL2 is a member of the retinoblastoma (RB) family of
tumor suppressor genes. Like RB, RBL2 binds members of
the DNA binding E2F transcription factor family that
regulate transcription of many genes associated with cell
cycle progression and cellular differentiation (33). Nota-
bly, RBL2 plays a role in preadipocyte proliferation and
differentiation, speciﬁcally binding E2F in the preadipo-
cyte quiescent nonproliferating and differentiated states
(29).
Adipocyte number is a major determinant of fat mass in
adults, and a recent study has shown that the number,
which is set in childhood and adolescence, remains rela-
tively constant over adult life (34). The A allele of
rs8050136 (which is in high LD with the A allele of
rs9939609) confers increased risk of obesity that is present
by the early age of 11 years (10). We observed that the A
allele of rs8050136 is strongly positively correlated with
RBL2 expression levels, raising the possibility that in-
creased levels of RBL2 may serve to limit clonal expansion
of the preadipocyte population during development. A
ﬁnite pool of adipocytes, with the environmental trigger of
excess consumption of highly processed energy-dense
food, may undergo cellular hypertrophy that is character-
ized by a hyperlipolytic state, resistance to insulin’s anti-
lipolytic effects, and increased nonesteriﬁed fatty acid ﬂux
(35). The effects of excess nonesteriﬁed fatty acids on
the liver and periphery promote insulin resistance, loss
of glucose homeostasis, and development of type 2
diabetes, providing a possible explanation as to why this
locus was originally identiﬁed based on association with
type 2 diabetes, which was dependent upon the pres-
ence of obesity.
In summary, we present data to suggest that the RBL2
gene may participate in mediating the biological conse-
quences of genetic variation in the fat mass and obesity-
associated locus within the FTO gene denoted by rs8050136.
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